Similar articles

• PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers.

  Alm A, Villumsen J. Alm A, et al. Arch Ophthalmol. 1991 Nov;109(11):1564-8. doi: 10.1001/archopht.1991.01080110100045. Arch Ophthalmol. 1991. PMID: 1755739 Clinical Trial.
• PhXA34--a prostaglandin F2 alpha analogue. Effect on intraocular pressure in patients with ocular hypertension.

  Villumsen J, Alm A. Villumsen J, et al. Br J Ophthalmol. 1992 Apr;76(4):214-7. doi: 10.1136/bjo.76.4.214. Br J Ophthalmol. 1992. PMID: 1390487 Free PMC article. Clinical Trial.
• Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension.

  Camras CB, Schumer RA, Marsk A, Lustgarten JS, Serle JB, Stjernschantz J, Bito LZ, Podos SM. Camras CB, et al. Arch Ophthalmol. 1992 Dec;110(12):1733-8. doi: 10.1001/archopht.1992.01080240073034. Arch Ophthalmol. 1992. PMID: 1463414 Clinical Trial.
• Assessment of ocular hypotensive mechanisms and additivity of antiglaucoma drugs in humans.

  Kaufman PF. Kaufman PF. Arch Ophthalmol. 1999 May;117(5):673-4. doi: 10.1001/archopht.117.5.673. Arch Ophthalmol. 1999. PMID: 10326968 Review. No abstract available.
• [Pharmacodynamics and pharmacokinetics of prostaglandins and their derivates in eye tissues].

  Szaliński MR, Turno-Krecicka A. Szaliński MR, et al. Klin Oczna. 2001;103(4-6):203-5. Klin Oczna. 2001. PMID: 11975019 Review. Polish.